id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-317057-c2bwky6e	Pickering, S.	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings	2020-06-04		.txt	text/plain	5304	269	53	A highly specific in-house ELISA was developed for the detection of anti-spike (S), -receptor binding domain (RBD) and -nucleocapsid (N) antibodies and used for the cross-comparison of ten commercial serological assays a chemiluminescence-based platform, two ELISAs and seven colloidal gold lateral flow immunoassays (LFIAs) on an identical panel of 110 SARS-CoV-2-positive samples and 50 pre-pandemic negatives. Accordingly, we developed a highly specific semi-quantitative 4 ELISA for the detection of anti-spike (S), -S receptor binding domain (RBD) and -N antibodies, and used this to cross-evaluate ten commercial antibody tests (seven lateral flow immunoassays (LFIAs), one chemiluminescent assay and two ELISAs) on a collection of 110 serum samples from confirmed RNA positive patients, and 50 pre-pandemic samples from March 2019. With no existing gold standard for the assessment of the serological response to SARS-CoV-2, we started by comparing commercial serological assays with the best performing configuration of the in-house ELISA (detection of anti-S IgM and IgG antibodies), which was also most likely to represent antibodies detected by the commercial tests.	./cache/cord-317057-c2bwky6e.txt	./txt/cord-317057-c2bwky6e.txt